title: Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
abstract: Since the benefit of prostate-specific antigen (PSA) screening remains controversial, new non-invasive biomarkers for prostate carcinoma (PCa) are still required. There is evidence that microRNAs (miRNAs) in whole peripheral blood can separate patients with localized prostate cancer from healthy individuals. However, the potential of blood-based miRNAs for the differential diagnosis of PCa and benign prostatic hyperplasia (BPH) has not been tested. We compared the miRNome from blood of PCa and BPH patients and further investigated the influence of the tumor volume, tumor-node-metastasis (TNM) classification, Gleason score, pretreatment risk status, and the pretreatment PSA value on the miRNA pattern. By microarray approach, we identified seven miRNAs that were significantly deregulated in PCa patients compared to BPH patients. Using quantitative real time PCR (qRT-PCR), we confirmed downregulation of hsa-miR-221* (now hsa-miR-221-5p) and hsa-miR-708* (now hsa-miR-708-3p) in PCa compared to BPH. Clinical parameters like PSA level, Gleason score, or TNM status seem to have only limited impact on the overall abundance of miRNAs in patients' blood, suggesting a no influence of these factors on the expression of deregulated miRNAs.
authors.affiliation: Institute of Human Genetics, Saarland University, Human Genetics, Building 60, 66421, Homburg, Germany.
authors.forename: Petra
authors.initials: P
authors.lastname: Leidinger
authors.affiliation: Institute of Human Genetics, Saarland University, Human Genetics, Building 60, 66421, Homburg, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Hart
authors.affiliation: Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.
authors.forename: Christina
authors.initials: C
authors.lastname: Backes
authors.affiliation: Institute of Human Genetics, Saarland University, Human Genetics, Building 60, 66421, Homburg, Germany.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Rheinheimer
authors.affiliation: Department of Urology, University Hospital Erlangen, 91054, Erlangen, Germany.
authors.forename: Bastian
authors.initials: B
authors.lastname: Keck
authors.affiliation: Department of Urology, University Hospital Erlangen, 91054, Erlangen, Germany.
authors.forename: Bernd
authors.initials: B
authors.lastname: Wullich
authors.affiliation: Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Keller
authors.affiliation: Institute of Human Genetics, Saarland University, Human Genetics, Building 60, 66421, Homburg, Germany. hgemee@uks.eu.
authors.forename: Eckart
authors.initials: E
authors.lastname: Meese
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs; D017430:Prostate-Specific Antigen
keywords: Benign prostatic hyperplasia; Expression analysis; MicroRNA; Microarray; Prostate cancer
references.citation: Br J Urol. 1988 Dec;62(6):584-9
references.pmid: 2464397
references.citation: Mol Cancer Res. 2014 Feb;12(2):250-63
references.pmid: 24337069
references.citation: Nat Methods. 2011 Sep 04;8(10):841-3
references.pmid: 21892151
references.citation: Int J Cancer. 2012 Aug 1;131(3):652-61
references.pmid: 22052531
references.citation: Mult Scler. 2014 Mar;20(3):295-303
references.pmid: 23836875
references.citation: World J Urol. 2007 Mar;25(1):3-9
references.pmid: 17364211
references.citation: Eur J Cancer. 2013 Apr;49(6):1374-403
references.pmid: 23485231
references.citation: Int J Mol Sci. 2013 May 24;14(6):11034-60
references.pmid: 23708103
references.citation: Tumour Biol. 2014 Oct;35(10):10529-38
references.pmid: 25060180
references.citation: FEBS J. 2014 Aug;281(16):3766-75
references.pmid: 24988946
references.citation: PLoS One. 2012;7(4):e34151
references.pmid: 22511932
references.citation: Cancer Immunol Immunother. 2010 Sep;59(9):1313-23
references.pmid: 20499060
references.citation: BMC Cancer. 2009 Oct 06;9:353
references.pmid: 19807914
references.citation: Methods Mol Biol. 2006;342:129-38
references.pmid: 16957372
references.citation: Urology. 1999 May;53(5):945-50
references.pmid: 10223488
references.citation: Endocr Relat Cancer. 2010 Jan 29;17(1):F1-17
references.pmid: 19779034
references.citation: Clin Cancer Res. 2004 Feb 15;10(4):1333-7
references.pmid: 14977833
references.citation: Br J Cancer. 2013 May 28;108(10):1925-30
references.pmid: 23632485
references.citation: Cancer Res. 1999 Dec 1;59(23):5975-9
references.pmid: 10606244
references.citation: Med Oncol. 2012 Dec;29(4):2877-88
references.pmid: 22215415
references.citation: Int J Oncol. 2009 Jul;35(1):87-96
references.pmid: 19513555
references.citation: Br J Cancer. 2010 Sep 7;103(6):918-24
references.pmid: 20736950
references.citation: Nucleic Acids Res. 2014 Jan;42(Database issue):D78-85
references.pmid: 24304892
references.citation: Cancer Res. 1980 Dec;40(12):4658-62
references.pmid: 6159971
references.citation: Br J Cancer. 2012 Feb 14;106(4):768-74
references.pmid: 22240788
references.citation: Control Clin Trials. 2000 Dec;21(6 Suppl):310S-328S
references.pmid: 11189685
references.citation: Eur Urol. 2014 Feb;65(2):329-36
references.pmid: 23954085
references.citation: J Clin Invest. 2010 Dec;120(12):4478-92
references.pmid: 21099110
references.citation: Am J Clin Exp Urol. 2014 Apr 05;2(1):62-70
references.pmid: 25374906
references.citation: Urology. 2006 Aug;68(2):352-6
references.pmid: 16904451
references.citation: J Endocrinol. 2004 Oct;183(1):69-78
references.pmid: 15525575
references.citation: Urol Oncol. 2010 Jan-Feb;28(1):4-13
references.pmid: 19117772
references.citation: Genome Biol. 2013 Jul 29;14(7):R78
references.pmid: 23895045
references.citation: J Clin Invest. 2010 Dec;120(12):4179-82
references.pmid: 21099103
references.citation: BMC Genomics. 2012 Aug 07;13:379
references.pmid: 22871070
references.citation: Prostate. 2011 May;71(6):604-14
references.pmid: 20945501
references.citation: Eur Urol. 2014 Jul;66(1):22-9
references.pmid: 24666839
references.citation: RNA. 2010 Dec;16(12):2493-502
references.pmid: 20966199
references.citation: Urology. 2011 May;77(5):1265.e9-16
references.pmid: 21539977
references.citation: Am J Pathol. 2010 Jan;176(1):393-401
references.pmid: 19948822
references.citation: RNA. 2003 Mar;9(3):277-9
references.pmid: 12592000
references.citation: Mol Cancer. 2014 Aug 30;13:202
references.pmid: 25175044
references.citation: Prostate. 2012 Sep 15;72(13):1443-52
references.pmid: 22298030
references.citation: Oncogene. 2006 Oct 9;25(46):6163-9
references.pmid: 17028595
references.citation: N Engl J Med. 2009 Mar 26;360(13):1320-8
references.pmid: 19297566
references.citation: Science. 2005 Oct 28;310(5748):644-8
references.pmid: 16254181
references.citation: Tumour Biol. 2014 Jul;35(7):7105-13
references.pmid: 24760272
references.citation: Cancer J. 2012 May-Jun;18(3):253-61
references.pmid: 22647362
references.citation: PLoS One. 2011;6(9):e24950
references.pmid: 21980368
references.citation: JAMA. 1998 Sep 16;280(11):969-74
references.pmid: 9749478
references.citation: Ann Surg Oncol. 2013 Dec;20 Suppl 3:S625-35
references.pmid: 23864307